

Supplementary Data

SUPPLEMENTARY TABLE S1. FREQUENCY OF PATIENTS WITH REMITTED NEUROPSYCHIATRIC INVENTORY SYMPTOMS DURING FOLLOW-UP

	From baseline to	Mild-AD patients			Moderate-AD patients		
		Men, N (%)	Women, N (%)	p	Men, N (%)	Women, N (%)	p
Delusions	3-Month follow-up	5 (4.7)	8 (8.3)	0.2875 ^a	5 (6.9)	10 (6.8)	1.000 ^b
	6-Month follow-up	6 (5.6)	9 (9.4)	0.3056 ^a	7 (9.6)	12 (8.2)	0.7230 ^a
	<i>N</i>	107 (100)	96 (100)		73 (100)	147 (100)	
Hallucinations	3-Month follow-up	3 (2.8)	5 (5.2)	0.4815 ^b	1 (1.3)	14 (9.5)	0.0215^a
	6-Month follow-up	2 (1.9)	8 (8.3)	0.0496^b	3 (4.0)	12 (8.2)	0.2425 ^a
	<i>N</i>	106 (100)	96 (100)		75 (100)	147 (100)	
Agitation	3-Month follow-up	4 (3.6)	10 (10.8)	0.0462^a	4 (5.3)	18 (12.1)	0.1093 ^a
	6-Month follow-up	6 (5.5)	13 (14.0)	0.0378^a	5 (6.7)	19 (12.8)	0.1647 ^a
	<i>N</i>	93 (100)	110 (100)		75 (100)	149 (100)	
Depression	3-Month follow-up	6 (5.7)	13 (13.1)	0.0653 ^a	4 (5.3)	9 (5.9)	1.0000 ^b
	6-Month follow-up	5 (4.7)	13 (13.1)	0.0334^a	7 (9.2)	23 (15.1)	0.2125 ^a
	<i>N</i>	106 (100)	99 (100)		76 (100)	152 (100)	
Anxiety	3-Month follow-up	8 (7.4)	11 (11.1)	0.3566 ^a	10 (12.7)	20 (13.2)	0.9147 ^a
	6-Month follow-up	10 (9.3)	10 (10.1)	0.8378 ^a	11 (13.9)	19 (12.5)	0.7600 ^a
	<i>N</i>	108 (100)	99 (100)		79 (100)	152 (100)	
Euphoria	3-Month follow-up	3 (2.9)	1 (1)	0.6228 ^b	2 (2.7)	8 (5.3)	0.5027 ^b
	6-Month follow-up	3 (2.9)	4 (4.2)	0.7114 ^b	2 (2.7)	8 (5.3)	0.5027 ^b
	<i>N</i>	105 (100)	96 (100)		75 (100)	151 (100)	
Apathy	3-Month follow-up	5 (4.6)	10 (10.2)	0.1153 ^a	3 (3.8)	15 (9.8)	0.1051 ^a
	6-Month follow-up	9 (8.2)	11 (11.2)	0.4575 ^a	4 (5.1)	19 (12.4)	0.0757 ^a
	<i>N</i>	110 (100)	98 (100)		79 (100)	153 (100)	
Disinhibition	3-Month follow-up	2 (1.9)	6 (6.3)	0.1524 ^b	3 (4.1)	8 (5.4)	1.0000 ^b
	6-Month follow-up	2 (1.2)	9 (9.5)	0.0182^a	5 (6.9)	15 (10.1)	0.4233 ^a
	<i>N</i>	106 (100)	95 (100)		73 (100)	148 (100)	
Irritability	3-Month follow-up	14 (13.1)	8 (8.3)	0.2660 ^a	11 (14.3)	21 (14.0)	0.9533 ^a
	6-Month follow-up	15 (14.0)	13 (13.4)	0.8983 ^a	12 (15.6)	22 (14.7)	0.8544 ^a
	<i>N</i>	107 (100)	97 (100)		77 (100)	150 (100)	
Aberrant motor behavior	3-Month follow-up	1 (0.9)	11 (11.6)	0.0015^a	5 (6.9)	15 (10.0)	0.4397 ^a
	6-Month follow-up	1 (0.9)	12 (12.6)	0.0008^a	7 (9.6)	18 (12.0)	0.5923 ^a
	<i>N</i>	106 (100)	95 (100)		73 (100)	150 (100)	
Nighttime behavior disturbances	3-Month follow-up	3 (3.1)	9 (9.7)	0.0596 ^a	4 (5.2)	16 (10.6)	0.1727 ^a
	6-Month follow-up	6 (6.1)	14 (15.1)	0.0439^a	7 (9.1)	19 (12.6)	0.4327 ^a
	<i>N</i>	98 (100)	93 (100)		77 (100)	151 (100)	
Appetite and eating abnormalities	3-Month follow-up	6 (6.0)	11 (11.7)	0.1604 ^a	4 (5.5)	10 (6.6)	1.0000 ^b
	6-Month follow-up	6 (6.0)	10 (10.6)	0.2405 ^a	3 (4.1)	17 (11.3)	0.0786 ^a
	<i>N</i>	100 (100)	94 (100)		73 (100)	151 (100)	

Results with *p*-values < 0.05 are in bold.

Percentages computed within class (mild-AD men, mild-AD women, moderate-AD men, moderate-AD women) over the total number of patients with available score within each domain.

^a χ^2 test (males vs. females).

^bTwo-sided Fisher's exact test (males vs. females).

AD, Alzheimer's disease; NPI, Neuropsychiatric Inventory.